S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

23andMe Stock Forecast, Price & News

+0.12 (+4.84%)
(As of 07/1/2022 08:44 PM ET)
Today's Range
50-Day Range
52-Week Range
1.58 million shs
Average Volume
3.61 million shs
Market Capitalization
$1.17 billion
P/E Ratio
Dividend Yield
Price Target

23andMe Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.50 Rating Score
92.3% Upside
5.00 Price Target
Short Interest
12.56% of Float Sold Short
Dividend Strength
News Sentiment
0.49mentions of 23andMe in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.36 out of 5 stars

Medical Sector

1035th out of 1,428 stocks

Pharmaceutical Preparations Industry

507th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter.

About 23andMe

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

ME Stock News Headlines

Head to Head Analysis: 23andMe (ME) versus Its Peers
23andMe Takes on Long Covid Impact - Bloomberg
23andMe (NASDAQ:ME) Hits New 12-Month Low at $2.13
23andMe has officially moved and downsized its HQ
23andMe stock falls on widening loss
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$-217.49 million
Pretax Margin


Sales & Book Value

Annual Sales
$271.89 million
Book Value
2.04 per share


Free Float
Market Cap
$1.17 billion
Not Optionable

23andMe Frequently Asked Questions

Should I buy or sell 23andMe stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" 23andMe stock.
View analyst ratings for 23andMe
or view top-rated stocks.

What is 23andMe's stock price forecast for 2022?

2 analysts have issued 1-year target prices for 23andMe's stock. Their ME stock forecasts range from 3.00 to 7.00. On average, they anticipate 23andMe's share price to reach 5.00 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for 23andMe
or view top-rated stocks among Wall Street analysts.

How has 23andMe's stock performed in 2022?

23andMe's stock was trading at 6.66 at the beginning of 2022. Since then, ME stock has decreased by 61.0% and is now trading at 2.60.
View the best growth stocks for 2022 here

When is 23andMe's next earnings date?

23andMe is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for 23andMe

How were 23andMe's earnings last quarter?

23andMe Holding Co. (NASDAQ:ME) announced its earnings results on Thursday, May, 26th. The company reported ($0.13) earnings per share (EPS) for the quarter. The firm earned $100.56 million during the quarter, compared to analysts' expectations of $102.79 million. 23andMe had a negative trailing twelve-month return on equity of 25.41% and a negative net margin of 79.99%. The firm's revenue for the quarter was up 13.5% compared to the same quarter last year.
View 23andMe's earnings history

What guidance has 23andMe issued on next quarter's earnings?

23andMe issued an update on its FY 2023 earnings guidance on Thursday, June, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $260.00 million-$280.00 million, compared to the consensus revenue estimate of $339.87 million.

Who are 23andMe's key executives?

23andMe's management team includes the following people:
  • Ms. Anne Wojcicki, Co-Founder, CEO, Pres & Director
  • Mr. Steven J. Schoch, Chief Financial and Accounting Officer (Age 63, Pay $582.83k)
  • Ms. Kathy L. Hibbs Esq., J.D., Chief Admin. Officer (Age 58, Pay $558.53k)
  • Dr. Kenneth J. Hillan Ch.B., M.B., Chief Therapeutics Officer (Age 61, Pay $557.62k)
  • Dr. Joseph R. Arron M.D., Ph.D., Chief Scientific Officer
  • Dr. Wade Walke, VP of Investor Relations (Age 56)
  • Ms. Jacquie Cooke Haggarty J.D., Gen. Counsel & Privacy Officer
  • Ms. Katie Watson, VP of Communications (Age 44)
  • Mr. Fred Mark Kohler, VP of People (Age 55)
  • Mr. Mike Polcari, VP & Chief Architect (Age 41)

What is 23andMe's stock symbol?

23andMe trades on the NASDAQ under the ticker symbol "ME."

How do I buy shares of 23andMe?

Shares of ME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 23andMe's stock price today?

One share of ME stock can currently be purchased for approximately 2.60.

How much money does 23andMe make?

23andMe (NASDAQ:ME) has a market capitalization of $1.17 billion and generates $271.89 million in revenue each year. The company earns $-217.49 million in net income (profit) each year or -0.66 on an earnings per share basis.

How many employees does 23andMe have?

23andMe employs 572 workers across the globe.

How can I contact 23andMe?

23andMe's mailing address is 65 BLEECKER STREET 6TH FLOOR, NEW YORK NY, 10012. The official website for 23andMe is vgacquisition.com. The company can be reached via phone at 650-938-6300 or via email at investors@23andme.com.

This page (NASDAQ:ME) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.